Phathom Pharmaceuticals Inc (PHAT) Stock Analysis

Phathom Pharmaceuticals Inc (PHAT) is a publicly traded company in the HEALTHCARE sector. It trades at $9.65, carries a market capitalization of $736.95M. This page summarizes the public market data, fundamentals, and frequently asked questions for PHAT, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Phathom Pharmaceuticals Inc currently has a Neutral sentiment score of 0.02.

About Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Florham Park, New Jersey, focusing on the development and commercialization of innovative therapies for gastrointestinal disorders. With a strong commitment to addressing unmet medical needs, Phathom is advancing a promising pipeline that includes novel treatment options, aiming to transform patient care in this critical therapeutic area. The company’s strategic emphasis on clinical development and potential p...

GNG Research Analysis

GNG Research scores Phathom Pharmaceuticals Inc (PHAT) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for PHAT.

Frequently Asked Questions

Does PHAT pay dividends?

Phathom Pharmaceuticals Inc (PHAT) does not currently pay a regular dividend.

What is PHAT's market cap?

Phathom Pharmaceuticals Inc (PHAT) has a market capitalization of $736.95M with a current stock price of $9.65.